title: Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay.
abstract: OBJECTIVE
  Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) is an adverse side effect of long-term bisphosphonate treatment. One theory of BP-ONJ etiology suggests a negative influence of these agents on angiogenesis and vascularization. This in vivo study analyzed the effects of bisphosphonates on angiogenesis in a 3D Matrigel assay.
  
  
  METHODS
  Matrigel plugs were implanted into fifty 6-8-week-old female nude mice. Ten animals each were treated either with clodronate, ibandronate, pamidronate, zoledronate, or carrier solution as controls. The microvessel density (MVD), microvessel area (MVA), and microvessel size (MVS) in Matrigel plugs were analyzed after 21 days of treatment by immunohistochemistry and exemplary 3D microvascular corrosion castings.
  
  
  RESULTS
  All bisphosphonates induced a statistically significant decrease of MVD (p each <0.001), whereby the nitrogen-containing bisphosphonates (N-BPs) demonstrated a clearly stronger effect than non-nitrogen-containing bisphosphonates (NN-BP) clodronate (control 166, clodronate 99, ibandronate 48, pamidronate 47, zoledronate 35 microvessels/mm(2)). Referring to MVA, similar results could be detected. MVS was significantly increased especially by ibandronate (103 %) compared to control group (p < 0.001). Scanning electron microscope scans of the corrosion castings confirmed these results.
  
  
  CONCLUSIONS
  The stronger influence on MVD by N-BPs compared to the NN-BP clodronate may explain for the lack of BP-ONJ after treatment with NN-BPs.
  
  
  CONCLUSIONS
  Ibandronate induced a strong increase of MVS. In combination with the reduced MVD, this could result only in a fractional reduced perfusion which might be an explanation for the lower occurrence of BP-ONJ in patients receiving ibandronate compared to patients receiving pamidronate or zoledronate.
authors.affiliation: Department of Oral and Maxillofacial Surgery, University Medical Center Mainz, Augustusplatz 2, 55131, Mainz, Germany.
authors.forename: A M
authors.initials: AM
authors.lastname: Pabst
authors.forename: T
authors.initials: T
authors.lastname: Ziebart
authors.forename: M
authors.initials: M
authors.lastname: Ackermann
authors.forename: M A
authors.initials: MA
authors.lastname: Konerding
authors.forename: C
authors.initials: C
authors.lastname: Walter
mesh_terms: D000818:Animals; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology*; D004164:Diphosphonates / Q000009:adverse effects / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D004164:Diphosphonates
references.citation: Oncology. 2009;76(3):209-11
references.pmid: 19212145
references.citation: Biochem Biophys Res Commun. 1997 Aug 28;237(3):483-7
references.pmid: 9299388
references.citation: Clin Oral Investig. 2010 Feb;14(1):35-41
references.pmid: 19294435
references.citation: J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75
references.pmid: 16243172
references.citation: J Bone Miner Res. 2000 Apr;15(4):613-20
references.pmid: 10780852
references.citation: Hematol Oncol. 2007 Dec;25(4):164-9
references.pmid: 17577204
references.citation: Mol Aspects Med. 2002 Dec;23(6S):S1-27
references.pmid: 12537983
references.citation: J Support Oncol. 2007 Nov-Dec;5(10):475-82
references.pmid: 18240669
references.citation: Clin Oral Investig. 2012 Feb;16(1):87-93
references.pmid: 21225298
references.citation: Life Sci. 2005 Aug 19;77(14):1740-9
references.pmid: 15955538
references.citation: Cardiovasc Res. 2001 Feb 16;49(3):507-21
references.pmid: 11166264
references.citation: J Oral Maxillofac Surg. 2004 May;62(5):527-34
references.pmid: 15122554
references.citation: Bone. 2003 Nov;33(5):805-11
references.pmid: 14623056
references.citation: J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410
references.pmid: 18022461
references.citation: Ann Oncol. 2003 Oct;14(10):1468-76
references.pmid: 14504045
references.citation: Support Care Cancer. 2007 Feb;15(2):197-202
references.pmid: 16941133
references.citation: J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7
references.pmid: 12966493
references.citation: J Oral Maxillofac Surg. 2008 May;66(5):839-47
references.pmid: 18423269
references.citation: Clin Cancer Res. 2002 May;8(5):1080-4
references.pmid: 12006522
references.citation: Oral Dis. 2011 Mar;17(2):194-9
references.pmid: 20796232
references.citation: Circ Res. 2008 Nov 21;103(11):1327-34
references.pmid: 18927463
references.citation: Circ Res. 2008 Oct 10;103(8):796-803
references.pmid: 18776043
references.citation: Cancer. 1997 Oct 15;80(8 Suppl):1652-60
references.pmid: 9362432
references.citation: Breast Cancer Res Treat. 2010 Jul;122(1):189-91
references.pmid: 20464477
references.citation: Trends Cardiovasc Med. 2000 Jul;10(5):223-8
references.pmid: 11282299
references.citation: Eur J Haematol. 2007 Jul;79(1):69-71
references.pmid: 17598839
references.citation: Clin Oral Investig. 2012 Aug;16(4):1153-9
references.pmid: 21938481
references.citation: Br J Oral Maxillofac Surg. 2010 Apr;48(3):221-3
references.pmid: 19836866
references.citation: Oral Maxillofac Surg. 2011 Mar;15(1):63-6
references.pmid: 20401503
references.citation: Clin Oral Investig. 2011 Feb;15(1):105-11
references.pmid: 20024592
references.citation: Oral Oncol. 2011 Mar;47(3):195-201
references.pmid: 21247791
references.citation: J Bone Miner Res. 1997 Sep;12(9):1358-67
references.pmid: 9286751
references.citation: Biochemistry. 1986 Jan 28;25(2):312-8
references.pmid: 2937447
references.citation: J Cell Biol. 1966 Jul;30(1):23-38
references.pmid: 5338131